NCT05965479 (DECIPHER) is a Phase 2 clinical trial of Trastuzumab deruxtecan in Gastrooesophageal Cancer, sponsored by University of Southampton.

Who is sponsoring NCT05965479?

NCT05965479 is sponsored by University of Southampton.

What drugs are being tested in NCT05965479?

Interventions in NCT05965479: Trastuzumab deruxtecan.

What condition does NCT05965479 study?

NCT05965479 studies Gastrooesophageal Cancer.

Is NCT05965479 still recruiting?

NCT05965479 is currently recruiting now. Last updated 12 November 2024.

Last reviewed 2024-11-12 · How we verify

NCT05965479: DECIPHER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Recruiting now Phase 2 Last updated 12 November 2024

What this trial tests

Phase 2 trial testing Trastuzumab deruxtecan in Gastrooesophageal Cancer in 25 participants. Currently enrolling.

Timeline

10 April 2024

Primary endpoint
31 March 2026

30 April 2028

Quick facts

Lead sponsor	University of Southampton
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	10 April 2024
Primary completion	31 March 2026
Estimated completion	30 April 2028
Sites	14 locations across United Kingdom

Drugs / interventions tested

Trastuzumab deruxtecan — full drug profile →

Conditions studied

Gastrooesophageal Cancer — all drugs for Gastrooesophageal Cancer →

Sponsor

University of Southampton

Who can join

18 and older, any sex, with Gastrooesophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from approximately 15 NHS secondary care sites.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Blood-Based Surveillance Biomarkers for Gastroesophageal Cancers.
Dadgar N, Anees M, Sherry C, Park HY, et al · · 2025 · cited 2× · PMID 41228346 · DOI 10.3390/cancers17213552
Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis.
Wang M, Xiong C, Wang S, Qiu Y, et al · · 2025 · cited 1× · PMID 41079086 · DOI 10.3389/fonc.2025.1608872
Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER.
Smyth E, Griffiths D, Cozens K, Ewings S, et al · · 2024 · PMID 41646956 · DOI 10.1016/j.esmogo.2024.100114

Verify or expand the search:

Other trials of Trastuzumab deruxtecan

Trials testing the same drug.

NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07086768 — Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metast · Phase 1 · not yet recruiting
NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
NCT07060807 — A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) · Phase 3 · recruiting
NCT06989112 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre · Phase 3 · recruiting

Other University of Southampton trials

Trials by the same sponsor.

NCT07531277 — Developing Resource Interventions for Healthcare Professionals and Patients to Improve Knowledge About Fertility in Prim · NA · not yet recruiting
NCT06923943 — Predicting Nurse Staffing Requirements From Routinely Collected Data · active not recruiting
NCT06692959 — A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer · Phase 2 · recruiting
NCT06815120 — A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent · NA · not yet recruiting
NCT06566157 — PROMOTE: The Effect of a Six Week Prebiotic Supplementation on Wellbeing of Young Adults. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05965479 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southampton
Last refreshed: 12 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05965479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing